Argitalpenak (32) SILVIA LÓPEZ FERNÁNDEZ argitalpenak

2024

  1. Diagnosis and treatment of myocarditis and inflammatory cardiomyopathy. Consensus document of the SEC-Working Group on Myocarditis

    Revista Espanola de Cardiologia

  2. Giant intramyocardial mass: a rare cause of bifascicular block

    European heart journal. Cardiovascular Imaging, Vol. 25, Núm. 3, pp. e112

2023

  1. Heart failure risk scores in advanced heart failure patients: insights from the LEVO-D registry

    ESC Heart Failure, Vol. 10, Núm. 5, pp. 2875-2881

  2. Influence of the medical treatment schedule in new diagnoses patients with heart failure and reduced ejection fraction

    Clinical Research in Cardiology

  3. Intermittent inotropic support with levosimendan in advanced heart failure as destination therapy: The LEVO-D registry

    ESC Heart Failure, Vol. 10, Núm. 2, pp. 1193-1204

2022

  1. Experience with the potassium binder patiromer in hyperkalaemia management in heart failure patients in real life

    ESC Heart Failure, Vol. 9, Núm. 5, pp. 3071-3078

  2. Gender differences in drug titration among heart failure patients with reduced ejection fraction in the ETIFIC trial

    Revista Espanola de Cardiologia, Vol. 75, Núm. 8, pp. 636-648

  3. Prevalence, Incidence, and Outcomes of Hyperkalaemia in Patients with Chronic Heart Failure and Reduced Ejection Fraction from a Spanish Multicentre Study: SPANIK-HF Design and Baseline Characteristics

    Journal of Clinical Medicine, Vol. 11, Núm. 5

  4. Técnicas de imagen no invasiva en cardiología

    Bases de la medicina interna. Fisiopatología y propedéutica médica: Volumen II (Avicam), pp. 141-166

2021

  1. Efficacy and safety of intermittent repeated levosimendan infusions in advanced heart failure patients: the LAICA study

    ESC Heart Failure, Vol. 8, Núm. 6, pp. 4820-4831

  2. Layer-Specific Global Longitudinal Strain Predicts Arrhythmic Risk in Arrhythmogenic Cardiomyopathy

    Frontiers in Cardiovascular Medicine, Vol. 8

2020

  1. Hyperkalemia in heart failure patients in Spain and its impact on guidelines and recommendations: ESC-EORP-HFA Heart Failure Long-Term Registry

    Revista Espanola de Cardiologia, Vol. 73, Núm. 4, pp. 313-323

  2. Myocardial fibrosis in arrhythmogenic cardiomyopathy: A genotype-phenotype correlation study

    European Heart Journal Cardiovascular Imaging, Vol. 21, Núm. 4, pp. 378-386

  3. One-year prognosis of patients with heart failure in Spain. ESC-EORP-HFA Heart Failure Long-Term Registry

    REC: CardioClinics, Vol. 55, Núm. 4, pp. 207-216

  4. Pronóstico al año en pacientes con insuficiencia cardiaca en España. Registro ESC-EORP-HFA Heart Failure Long-Term

    REC: CardioClinics, Vol. 55, Núm. 4, pp. 207-216

2019

  1. Sacubitril/valsartan eligibility and outcomes in the ESC-EORP-HFA Heart Failure Long-Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM-HF trial, ESC guidelines, and real world

    European Journal of Heart Failure, Vol. 21, Núm. 11, pp. 1383-1397

2018

  1. Novel Desmin Mutation p.Glu401Asp Impairs Filament Formation, Disrupts Cell Membrane Integrity, and Causes Severe Arrhythmogenic Left Ventricular Cardiomyopathy/Dysplasia

    Circulation, Vol. 137, Núm. 15, pp. 1595-1610

  2. Performance of Prognostic Risk Scores in Chronic Heart Failure Patients Enrolled in the European Society of Cardiology Heart Failure Long-Term Registry

    JACC: Heart Failure, Vol. 6, Núm. 6, pp. 452-462

  3. Prognostic value of nocturnal pulse oximetry in patients with heart failure

    Medicina Clinica, Vol. 150, Núm. 10, pp. 383-386

2017

  1. Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC Heart Failure Long-Term Registry

    European Journal of Heart Failure, Vol. 19, Núm. 10, pp. 1242-1254